SCHEMBL3160356

SCHEMBL3160356

CCOC(=O)N1CCN(C(=O)c2cc3cc(C(=O)N4CCN(C(C)C)CC4)ccc3n2C(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
CYP2C19 P33261 2/20 0.50
POLB P06746 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HRH3 Q9Y5N1 2/20 0.49
CYP2D6 P10635 1/20 0.49
LMNA P02545 1/20 0.47
GAA P10253 2/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 1/20 0.46
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CHRNA7 P36544 1/20 0.44
SMYD3 Q9H7B4 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3160773 0.96 CHRNA7 (0.48) ALDH1A1CYP2C19POLBNPSR1HRH3
SCHEMBL3160789 0.86 KMT2A (0.50) ALDH1A1CYP2C19POLBNPSR1LMNA
SCHEMBL27787697 0.86 HRH3 (0.51) HRH3CYP2D6KMT2ACHRNA7
SCHEMBL3167147 0.85 HRH3 (0.50) HRH3CYP2D6CHRNA7
SCHEMBL3165664 0.84 HRH3 (0.49) HRH3CYP2D6CHRNA7
SCHEMBL3543062 0.83 HRH3 (0.66) HRH3CYP2D6KMT2ACHRNA7
SCHEMBL3543762 0.83 HRH3 (0.48) HRH3CYP2D6KMT2AHPGDCHRNA7
SCHEMBL3160495 0.83 CHRNA7 (0.54) ALDH1A1HRH3CYP2D6CHRNA7
SCHEMBL27739848 0.83 HRH3 (0.48) HRH3CYP2D6KMT2AHPGDCHRNA7
SCHEMBL3160074 0.82 HRH3 (0.52) HRH3CYP2D6GAAKMT2ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7648979-B2 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives HOFFMANN-LA ROCHE INC. (US) 2010-01-19 US disclosed
EP-2118059-A1 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS F. Hoffmann-Roche AG (CH) 2009-11-18 EP disclosed
WO-2008095823-A1 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-14 WO disclosed
US-20080188487-A1 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188487-A1 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES HRH4, HRH3, HRH2 ALDH1A1 577/4885CYP2C19 363/4885POLB 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.